RxDoctor Payments Data

Donna Benford, DO

Family Medicine · Fenton, MINPI 1073670154

Payments from drug & device makers

$6,115in general payments, 2019–2025

Across 348 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$990
  • AstraZeneca$903
  • Pfizer$692
  • GSK$559
  • Lilly USA, LLC$364
  • Novo Nordisk$306
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$6,109100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,115 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$63,632
Medicare patients
158
Services billed
1,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$62,884
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$48,959
FarxigaDapagliflozin Propanediol46$43,318
XareltoRivaroxaban24$36,292
JardianceEmpagliflozin17$27,256
MyrbetriqMirabegron18$21,248
JanuviaSitagliptin Phosphate16$17,916
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$9,844
Levothyroxine Sodium466$5,950
Atorvastatin Calcium334$5,320
Raloxifene Hcl72$4,123
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,394
ValacyclovirValacyclovir Hcl52$3,341
Duloxetine Hcl95$3,108
Omeprazole155$2,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$692$62,88442 claims
GSKTrelegy Ellipta$559$48,95947 claims
AstraZenecaFarxiga$903$43,31846 claims
Boehringer IngelheimJardiance$38$27,25617 claims
Astellas Pharma US IncMyrbetriq$256$21,24818 claims
MerckJanuvia$45$17,91616 claims
AbbVieSynthroid, Armour Thyroid$990$3,99844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Fenton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →